The study contract provides for the utilization of Celator’s proprietary technology in an ongoing drug advancement and life-cycle management system at Cephalon. ‘We are pleased that our progress to day enables Cephalon and Celator to advance this promising work,’ said Scott Jackson, ceo, Celator Pharmaceuticals. ‘It really is rewarding to possess a organization of Cephalon’s stature demonstrate the potential of our technology in its portfolio and make the ongoing economic commitment to continue this research.’ Related StoriesNew RNA test of blood platelets may be used to detect location of cancerFDA grants accelerated authorization for Tagrisso to treat sufferers with advanced NSCLCCornell biomedical engineers develop 'very natural killer cells' to destroy tumor cells in lymph nodesTerms and conditions of the study agreement are confidential.About 13 % of women that are pregnant and new mothers have major depression, according to federal government estimates. Previous research suggests kids of depressed parents will become depressed themselves. But those scholarly studies occurred years after birth, according to the experts, and they wished to look previously to see if the brain changes could be passed through birth. Experts led by Dr. Anqi Qiu, a co-employee professor at National University who specializes in medical imaging, recruited 157 women that are pregnant. They finished a questionnaire that measured major depression at week 26 of pregnancy. Then inside a fortnight of being born, babies received imaging scans of their brains.